Skip to content

Clinical Study on the Changes in Gastrointestinal Microbiota Before and After Vonoprazan-Tetracycline Dual Therapy for Helicobacter pylori

Clinical Study on the Changes in Gastrointestinal Microbiota Before and After Vonoprazan-Tetracycline Dual Therapy for Helicobacter pylori

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600120137
Enrollment
Unknown
Registered
2026-03-10
Start date
2026-03-10
Completion date
Unknown
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

positive in Helicobacter pylori infection

Interventions

VT dual group:NA

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 18 to 70 years, of any sex; 2. Clinically evaluated by a physician and scheduled to receive Vonoprazan-Tetracycline (VT) dual therapy for Helicobacter pylori eradication; 3. Willing to participate voluntarily and able to comply with the study procedures.

Exclusion criteria

Exclusion criteria: 1. Long-term use of medications that may affect the gastrointestinal microecology, such as oral probiotics. 2. Previous Helicobacter pylori eradication therapy that included tetracycline. 3. Pregnant or breastfeeding women. 4. Use of medications within 4 weeks prior to treatment that may influence the results, such as bismuth agents, acid suppressants (PPI or P-CAB), or antibiotics. 5. History of gastrointestinal surgery. 6. Presence of other serious diseases that could interfere with the evaluation of this study, such as severe liver disease, pulmonary disease, hematological disorders, endocrine disorders, cardiovascular disease, renal disease, malignant tumors, or alcohol abuse. 7. Concurrent medical conditions that may affect the gastrointestinal microecology. 8. Participation in another drug study within 3 months prior to the use of the study drug. 9. Inability to accurately express subjective symptoms, such as in patients with psychosis or severe psychoneurosis, rendering them unable to cooperate with the study. 10. Other conditions deemed by the investigator as inappropriate for participation in this study.

Design outcomes

Primary

MeasureTime frame
Changes in fecal 16S rRNA sequencing and metagenomic sequencing before treatment and at various time points after treatment;

Secondary

MeasureTime frame
Detection of antibiotic resistance genes in fecal bacteria;

Countries

China

Contacts

Public ContactGao Wen

Peking University First Hospital

gaowenhi@163.com+86 10 83572204

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 20, 2026